ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis

This study has been completed.

Sponsors and Collaborators: FDA Office of Orphan Products Development
Medical University of South Carolina
Information provided by: FDA Office of Orphan Products Development
ClinicalTrials.gov Identifier: NCT00010439
  Purpose

OBJECTIVES:

I. Determine the effects of alendronate sodium on skeletal remodeling and bone mineral density of the hip and spine in children with high-turnover idiopathic juvenile osteoporosis.


Condition Intervention Phase
Osteoporosis
Drug: alendronate
Phase II

MedlinePlus related topics:   Minerals    Osteoporosis   

ChemIDplus related topics:   Alendronate    Alendronate sodium   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:   A Non-Randomized, Open-Label, Prospective, Non-Controlled, 12-Month Clinical Trial to Determine the Effects of Alendronate 35 or 70 mg/Week Depending Upon Body Weight, in Children and Adolescent With IJO

Further study details as provided by FDA Office of Orphan Products Development:

Primary Outcome Measures:
  • Bone Mineral Density (BMD) of the lumbar spine and hip at 12 months. [ Time Frame: at 12 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Fracture rate before and during therapy; bone biopsies and biochemical markers to determine whether or not the primary effect of therapy is on bone formation or resorption; bone biopsies will also be used to assess the safety. [ Time Frame: at 12 months ] [ Designated as safety issue: Yes ]

Enrollment:   10
Study Start Date:   September 2000
Study Completion Date:   October 2003
Primary Completion Date:   October 2003 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Experimental
Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium suplement daily.
Drug: alendronate
Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.

Detailed Description:

PROTOCOL OUTLINE:

Patients receive oral alendronate sodium daily for 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.

  Eligibility
Ages Eligible for Study:   5 Years to 14 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Eligibility Criteria:

  • 5-14 years of age
  • Weight 20 kg or greater
  • History of one or more atraumatic fracture
  • Sexual development no greater than Tanner II
  • Osteoporosis by DXA (Diagnosis of high-turnover osteoporosis with no underlying cause (e.g., malignancy, hyperthyroidism, hyperparathyroidism, or vitamin D intoxication)

Inclusion Criteria:

  • Male and female children with a history of one or more atraumatic fractures, or evidence of one or more compression fractures on radiographs of the spine (reduction of >20%).
  • Bone mineral density by DXA at 2 standard deviations (SD) below normal mean for age (Z-score at least 2 SD below normal mean at the lumbar spine or hip)
  • Parental consent (and patient assent after age 12 years) to participate in the study.
  • Sexual development at Tanner stage II or less (Prepubertal stage)
  • Weight 20kg and more

Exclusion Criteria:

  • History of severe gastritis or reflux
  • Marked kyphoscoliosis or inability to sit or stand for at least 30 minutes.
  • Abnormalities of the esophagus that delay emptying (e.g., strictures or achalasia)
  • Hypersensitivity to bisphosphonates
  • Uncorrected hypocalcemia
  • History of gastric or duodenal ulcers
  • Renal dysfunction as indicated by serum Creatinine greater than 1.5 mg/dL
  • Liver dysfunction as indicated by serum SGPT greater than 2 times upper limit of normal for age or serum total bilirubin greater than 2.0 mg/dL
  • Diagnosis of osteogenesis imperfecta (including family history) or blue sclerae or deafness
  • Diagnosis of active rickets, osteomalacia, or bone alkaline phosphatase > 2 times normal for age
  • Severe gastritis or reflux
  • Pregnancy
  • Anorexia Nervosa

    • Prior/Concurrent Therapy—
  • Prior course of prednisone allowed
  • No concurrent prednisone except inhaled steroids
  • No concurrent high-dose glucocorticoids
  • No concurrent salmon calcitonin
  • No other concurrent bisphosphonates
  • No concurrent long-term anti-seizure medication
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00010439

Locations
United States, South Carolina
Medical University of South Carolina    
      Charleston, South Carolina, United States, 29425

Sponsors and Collaborators
FDA Office of Orphan Products Development
Medical University of South Carolina

Investigators
Study Chair:     L. Lyndon Key, Jr.     Medical University of South Carolina    
  More Information


"Click here for more information about this study:"  This link exits the ClinicalTrials.gov site
 

Publications of Results:
1. Key LL Jr., Ries w, Madyastha P, Reed F: Juvenile Osteoporosis: recognizing the risk. J Pediatr Endocrinol Metab. 2003 May; 16 Suppl 3:683-6, PMID: 12795371 2. P Madyastha, W Ries, B Hollis, F Reed, L Key. Alendronate improved bone mineral density in patients with juvenile osteoporosis. JBMR 20:Suppl 1, page S400, 2005.
 

Responsible Party:   Medical University of South Carolina ( L Lyndon Key, MD., Prof and Chairman )
Study ID Numbers:   199/15705, MUSC-FDR001847
First Received:   February 2, 2001
Last Updated:   December 26, 2007
ClinicalTrials.gov Identifier:   NCT00010439
Health Authority:   United States: Food and Drug Administration

Keywords provided by FDA Office of Orphan Products Development:
arthritis & connective tissue diseases  
idiopathic juvenile osteoporosis  
rare disease  

Study placed in the following topic categories:
Body Weight
Musculoskeletal Diseases
Alendronate
Arthritis
Rare Diseases
Connective Tissue Diseases
Osteoporosis
Bone Diseases, Metabolic
Juvenile osteoporosis
Bone Diseases

Additional relevant MeSH terms:
Physiological Effects of Drugs
Bone Density Conservation Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 15, 2008




Links to all studies - primarily for crawlers